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Buruli Ulcer 
Lesions in HIV-
Positive Patient 
To the Editor:  Mycobacterium 
ulcerans disease (Buruli ulcer) is a 
neglected and emerging tropical dis-
ease (1). It often leads to extensive 
destruction of skin and soft tissue with 
the formation of large ulcers (2). In 
2004, the World Health Organization 
(WHO) recommended the combina-
tion treatment of rifampin/streptomy-
cin for patients with this disease (3). 
According to WHO, development of 
new antimicrobial drug treatment is 
one of the major advances since the 
establishment of the Global Buruli 
Ulcer Initiative (1). Treatment with 
rifampin/streptomycin for >4 weeks 
can inhibit the growth of M. ulcerans 
in preulcerative lesions (4). In other 
patients, despite 4 weeks of treatment, 
lesions may deteriorate. Whether this 
treatment is less efﬁ  cacious in persons 
with HIV infection is unknown.
In August 2008, a 35-year-old 
man was referred to the Medical Cen-
tre of the Democratic Republic of 
Congo for assessment of chronic ul-
cers. Lesions had appeared 12 months 
earlier when the patient was living in 
Kafufu/Luremo, a new focus of Buruli 
ulcer in Angola (5). Tissue specimens 
were subjected to Ziehl-Neelsen stain-
ing, culture, and PCR. All results were 
positive for M. ulcerans. Histopatho-
logic analysis of formalin-ﬁ  xed tissue 
conﬁ  rmed the diagnosis of active Bu-
ruli ulcer. We treated the patient with 
a combination of rifampin (10 mg/kg/
day, orally) and streptomycin (15 mg/
kg/day, by intramuscular injection). 
Wound dressings containing an aque-
ous solution of chloramine/metron-
idazole/nitrofurantoine were changed 
daily (6). For logistic reasons, surgery 
(large excision) under general anes-
thesia was not possible.
Characteristics of the patient are 
shown in the online Technical Appen-
dix (www.cdc.gov/EID/content/16/4/
738-Techapp.pdf). At the start of treat-
ment, the patient had a large ulcer on 
the right leg and thigh, a nodule 2 
cm in diameter on the left thigh, and 
a plaque 8 cm in diameter on the left 
thigh. After 2 weeks of treatment, the 
size of the large ulcer had increased. 
After 4 weeks, the nodule became an 
ulcer 6 cm in diameter, and the plaque 
became a large ulcer 15 cm in diameter 
with a satellite ulcer 2 cm in diameter. 
After 8 weeks, we observed enlarge-
ment of all lesions and the appearance 
of an ulcer on the left wrist. Treatment 
was continued for an additional 4 
weeks (total 12 weeks). Radiologic in-
vestigation did not disclose any bone 
destruction.
The patient was positive for HIV 
by the Determine HIV-1/2 test (Ab-
bott Laboratories, Dainabot Co. Ltd., 
Tokyo, Japan), the Uni-Gold HIV 
test (Trinity Biotech PLC, Bray, Ire-
land), and the Genie II HIV-1/HIV-2 
test (Bio-Rad, Marnes-la-Coquette, 
France). Results of PCR for M. ulcer-
ans and Ziehl-Neelsen staining were 
positive for all specimens obtained 
during the 8 weeks of initial treat-
ment. The patient died 2 weeks after 
treatment ended, just when antiretro-
viral treatment had been scheduled to 
begin.
Although the patient did not re-
spond clinically to treatment with 
rifampin/streptomycin, whether the 
treatment also failed microbiological-
ly is more difﬁ  cult to prove. Results of 
PCRs performed during treatment re-
mained positive. However, PCR does 
not differentiate between living and 
dead M. ulcerans bacteria. Therefore, 
our positive results suggest, but do not 
prove, treatment failure. The positive 
culture after 2 weeks of treatment also 
suggests treatment failure but cultures 
obtained at 4 and 8 weeks were con-
taminated. However, culturing M. ul-
cerans bacteria is difﬁ  cult, especially 
if samples must be transported (7).
Patients with Buruli ulcer may 
also be infected with HIV. In a study 
conducted during January 2002–Au-
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gust 2003 that compared HIV preva-
lence in 426 patients with Buruli 
ulcer and 613 controls in southern Be-
nin, HIV prevalence among patients 
with Buruli ulcer was higher (2.6%, 
11/426) than among controls (0.3%, 
2/613) (odds ratio 8.1) (8). However, 
none of these reported HIV-positive 
patients with Buruli ulcer were treated 
with rifampin/streptomycin and anti-
retroviral therapy (8).
A study of 224 patients with Bu-
ruli ulcer in Benin that evaluated the 
WHO-recommended regimen of 8 
weeks of treatment with rifampin/
streptomycin showed promising re-
sults (9). Chemotherapy alone was 
successful in achieving a cure rate 
of 47% of patients and was effective 
against ulcers <5 cm in diameter (9). 
However, HIV testing was not per-
formed in this study. In Spain, an HIV-
positive patient with aggressive, mul-
tifocal Buruli ulcer and osteomyelitis 
was cured by surgery, broad-spectrum 
antimicrobial drugs (not rifampin/
streptomycin), and antiretroviral drugs 
(10). Relapse was not reported in this 
study at 6-months follow-up.
For control of Buruli ulcer in 
HIV-positive patients, patients should 
be treated with rifampin/streptomycin 
and antiretroviral therapy to stimulate 
their immunity. Our report emphasizes 
the urgent need to evaluate treatment 
of HIV-positive patients infected with 
Buruli ulcer with rifampin/streptomy-
cin and antiretroviral drugs.
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Hantavirus 
Pulmonary 
Syndrome, 
French Guiana
To the Editor: Hantaviruses are 
rodent-borne negative-sense RNA vi-
ruses belonging to the Bunyaviridae 
family, genus Hantavirus. Since the 
ﬁ  rst report of a hantavirus in 1993 in 
the United States (1), different viruses 
belonging to this genus have been re-
ported in the Americas (2–5). These 
New World viruses are responsible for 
a disease called hantavirus pulmonary 
syndrome (HPS), a respiratory ill-
ness caused by the inhalation of dust 
contaminated by rodent feces or urine 
containing the virus (6–8).
Until recently, no information 
was available concerning the presence 
of hantaviruses in French Guiana, a 
French overseas department (admin-
istrative unit) in South America. Nev-
ertheless, the description of atypical 
pneumonia cases not related to any 
known etiologic agent and the iden-
tiﬁ   cation of hantavirus reservoirs in 
neighboring countries led us to con-
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